1. Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19)
- Author
-
Oliver Grundmann and Habeb Al-Kamel
- Subjects
Pharmacology ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Outbreak ,General Medicine ,Glycyrrhizic Acid ,medicine.disease_cause ,Virology ,World health ,Virus ,COVID-19 Drug Treatment ,chemistry.chemical_compound ,chemistry ,Drug Discovery ,Pandemic ,medicine ,Humans ,Glycyrrhizin ,business ,Coronavirus - Abstract
COVID-19 is an emerging viral infection of zoonotic origin that is closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused an outbreak in 2003. Therefore, scientists named the new virus SARS-CoV-2. On March 11, 2020, The World Health Organization (WHO) recognized COVID-19 as a global pandemic. At present, three vaccines have been approved or are being considered for approval by national regulatory agencies to immunize against COVID- 19. However, the vaccines do not remain widely available, and no specific treatment against the virus is available. The pathogenesis and proliferation pathways of SARS-CoV-2 are still not well known. Thus, in this article, the saponin glycyrrhizin is discussed as a new potential therapeutic agent of natural origin (licorice root, Glycyrrhiza glabra) for the potential treatment of COVID-19 infections.
- Published
- 2021